Revealdx logo

Revealdx

reveal-dx.com

RevealDx develops RevealAI-Lung, computer-aided diagnostic software that analyzes radiomic features in chest CT scans and gives radiologists a malignancy similarity score for individual lung nodules. It aims to help clinicians identify which nodules need earlier follow-up and guide patients onto the right care pathway sooner.

Facts

HQ
Seattle, WA
Sectors
Healthcare, Medical Software, AI/ML, Radiology
Type
Corporation Seattle business license
Registered name
Precision Medical Ventures Inc Seattle business license
Stage
Seed
Founders
Michael Calhoun, PhD

Is this your organization? Claim it

4DMedical Invests $3.4M in RevealDx and Gains Rights to Distribute FDA-Cleared RevealAI-Lung Across US, Europe, Australia, New Zealand

RevealDx secured a $3.4 million strategic investment from 4DMedical and a distribution agreement to expand its FDA-cleared RevealAI-Lung nodule characterization software across the US, Europe, Australia, and New Zealand, integrating into clinical workflows and contextflow’s platform to help radiologists stratify lung cancer risk.

RevealDx secures $3.4M from 4D Medical and global distribution for RevealAI-Lung across US, Europe, Australia, New Zealand

RevealDx raised $3.4 million from 4D Medical and struck a distribution agreement to have 4D Medical sell its RevealAI-Lung diagnostic software across the US, Europe, Australia, and New Zealand; the tool scores incidental lung nodules on CT using a Malignancy Similarity Index to guide radiologist follow-up. The software is validated on over 1,500 patients, holds CE, TGA and FDA clearances, and is reimbursable by Medicare under CPT codes 0721T and 0722T.

See all 7 stories, episodes and videos about Revealdx.

People

  • Chris Wood Executive, Chief Executive Officer

Online